Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following hematologic malignancies:~  * Acute myeloid leukemia (AML), meeting 1 of the following criteria:~    * AML beyond first complete remission (CR1)~   * Refractory AML~   * AML arising from myelodysplastic syndromes (MDS)~   * Secondary AML~ * MDS~    * Refractory anemia with excess blasts with \> 10% blasts in bone marrow~ * Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:~    * ALL in CR1 with 1 of the following high-risk features:~      * Philadelphia chromosome (Ph)-positive disease~     * Less than 1 year of age at diagnosis~     * Cytogenetic abnormalities involving chromosome 11q23~   * ALL beyond CR1~   * Refractory ALL~ * Chronic myeloid leukemia beyond first chronic phase~ * Chronic myelomonocytic leukemia~ * Chronic lymphocytic leukemia~    * Stage III-IV disease~   * Does not meet criteria for other bone marrow transplantation (BMT) studies~ * Myeloproliferative disorders~    * Ph-negative disease~ * Hodgkin's or non-Hodgkin's lymphoma~    * Chemotherapy-resistant disease~ * Paroxysmal nocturnal hemoglobinuria with life-threatening thrombosis~ * Multiple myeloma~    * Stage II or III disease~* Very high-risk disease~  * Having an unrelated donor is considered a high-risk condition~* Meets medical criteria for myeloablative BMT for the Sidney Kimmel Comprehensive Cancer Center~* Bone marrow donor available, meeting 1 of the following criteria:~  * Genotypically HLA-identical sibling~ * Phenotypically matched first-degree relative~ * Unrelated donor molecularly matched at HLA-A, -B, -C, -DRB1, and -DQB1~PATIENT CHARACTERISTICS:~Age~* 6 months to 65 years~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* No concurrent dexamethasone as an antiemetic during immunosuppression therapy~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No concurrent immunosuppressants until ≥ 24 hours after the completion of cyclophosphamide (post-transplantation)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bone marrow transplant (Type: EXPERIMENTAL): Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).